Results 31 to 40 of about 3,667 (197)

Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis. [PDF]

J Antimicrob Chemother, 2018
Background: Atovaquone/proguanil, registered as Malarone®, is a fixed-dose combination recommended for first-line treatment of uncomplicated Plasmodium falciparum malaria in non-endemic countries and its prevention in travellers.
Staines HM, Burrow R, Teo BH, Chis Ster I, Kremsner PG, Krishna S.   +5 more
europepmc   +2 more sources

Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola

Malaria Journal, 2006
Background The fixed dose combination atovaquone-proguanil is a recently introduced antimalarial for treatment and prophylaxis of Plasmodium falciparum malaria. It is highly effective with a good tolerability profile and a convenient prophylactic regimen.
Varandas Luís, Bom Joana, Quinhentos Vatúsia, Benchimol Carla, Nogueira Fátima, Pimentel Sónia, do Rosário Virgílio, Bernardino Luís   +7 more
doaj   +1 more source

Malarone treatment failure not associated with previously described mutations in the cytochrome b gene

Malaria Journal, 2004
Malarone® (atovaquone-proguanil) is an effective drug for the treatment and prophylaxis of multidrug-resistant falciparum malaria. However, first cases of resistance have been reported, which are associated with mutations at codon 268 of the parasite's ...
Mockenhaupt Frank P, Gruss Holger, Muehlen Marion, Wichmann Ole, Suttorp Norbert, Jelinek Tomas   +5 more
doaj   +1 more source

Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker

Malaria Journal, 2003
Background Resistance of Plasmodium falciparum to atovaquone in vitro and in vivo has been associated to mutations in the parasite cytochrome b gene. Methods Cultures were sequentially subjected to increasing doses of atovaquone alone or in combination ...
Salanti Ali, Alifrangis Michael, Schwöbel Babett, Jelinek Tomas   +3 more
doaj   +1 more source

Acute Hepatitis and Atovaquone/Proguanil [PDF]

Journal of Travel Medicine, 2006
A 31-year-old healthy man developed acute hepatitis after receiving atovaquone (250 mg) and proguanil (100 mg) for malaria prophylaxis daily for 25 days. Although atovaquone/proguanil is generally well-tolerated, this case highlights the hepatotoxic potential with considerable morbidity and should alert physicians to this harmful side effect.
Matthias, Grieshaber, Jürg, Lämmli, Louis, Marcus   +2 more
openaire   +2 more sources

Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast

Malaria Journal, 2012
The increased spread of drug-resistant malaria highlights the need for alternative drugs for treatment and chemoprophylaxis. The combination of atovaquone‐proguanil (Malarone®) has shown high efficacy against Plasmodium falciparum with only mild side ...
Wurtz Nathalie, Pascual Aurélie, Marin-Jauffre Adeline, Bouchiba Housem, Benoit Nicolas, Desbordes Marc, Martelloni Maryse, de Santi Vincent, Richa Georges, Taudon Nicolas, Pradines Bruno, Briolant Sébastien   +11 more
doaj   +1 more source

Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum.

, 2004
A modified fixed-ratio isobologram method for studying the in vitro interactions between antiplasmodial drugs is described. This method was used to examine the interactions between atovaquone, proguanil, and dihydroartemisinin.
Quinton L. Fivelman, Warhurst, David C, Ipemida S. Adagu, Fivelman, Quinton L, Adagu, Ipemida S, David C. Warhurst   +5 more
core   +1 more source

Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa

Malaria Journal, 2006
Background In vitro and in vivo resistance of Plasmodium falciparum to atovaquone or atovaquone-proguanil hydrochloride combination has been associated to two point mutations in the parasite cytochrome b (cytb) gene (Tyr268Ser and Tyr268Asn).
Kyle Dennis E, Sowunmi Akintunde, Sarr Ousmane, Milner Danny, Folarin Onikepe A, Gbotosho Grace O, Happi Christian T, Milhous Wilbur K, Wirth Dyann F, Oduola Ayoade MJ   +9 more
doaj   +1 more source

Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial

Malaria Journal, 2008
Background Due to increasing drug resistance, artemisinin-based combination chemotherapy (ACT) has become the first-line treatment of falciparum malaria in many endemic countries. However, irreversible ototoxicity associated with artemether/lumefantrine (
Krause Eike, Girma Tsinuel, Mamo Yoseph, Berens-Riha Nicole, Miranda Isabel, Eshetu Teferi, Gürkov Robert, Schmidt Michael, Hempel John-Martin, Löscher Thomas   +9 more
doaj   +1 more source

Molecular surveillance of mutations in the cytochrome b gene of Plasmodium falciparum in Gabon and Ethiopia

Malaria Journal, 2006
Background Atovaquone is part of the antimalarial drug combination atovaquone-proguanil (Malarone®) and inhibits the cytochrome bc1 complex of the electron transport chain in Plasmodium spp.
Kremsner Peter G, Hailu Asrat, Gebru Tamirat, Kun Jürgen FJ, Grobusch Martin P   +4 more
doaj   +1 more source